Westwood Salient Enhanced Midstream Income ETF

MDST · ETF

$29.12+$0.53 (+1.85%)TodayMarket closed ·
Prev close $28.59

About MDST

MDST was created on 2024-04-09 by Westwood. The fund's investment portfolio concentrates primarily on energy equity. The ETF currently has 302.53m in AUM and 27 holdings. MDST is an actively managed fund that invests in midstream North American companies and US master limited partnerships (MLPs). In addition, the fund enhances income through covered call options.

Issuer
Westwood
Expense ratio
0.8%
Assets under management
$295.17M
Inception
Apr 9, 2024
Asset class
Equity

MDST key statistics

Price-earnings ratio
0.00
Average volume
71.07K
Volume
31.44K
Open price
$28.58
High today
$29.18
Low today
$28.58
52 Week high
$30.43
52 Week low
$24.93

Westwood Salient Enhanced Midstream Income ETF (MDST) at a glance

As of Oct 23, 2026, Westwood Salient Enhanced Midstream Income ETF (MDST) shares are priced at $29.12, giving the company a price-to-earnings ratio of 0.00.

Today the fund has traded between $28.58 and $29.18. The current price is 1.9% above the day's low and 0.2% below its high.

Volume so far is 31.44K shares, below the average of 71.07K shares a day.

Over the past year Westwood Salient Enhanced Midstream Income ETF has ranged from $24.93 to $30.43, and now sits 76% of the way up that range.

MDST news

  • Lekha Gupta

    Kinder Morgan's Backlog And Demand Trends Keep 2025 EBITDA On Track, Says Goldman

  • Press releaseGlobe Newswire

    Westwood Holdings Group, Inc. Reports Second Quarter 2024 Results

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.